GBS Polysaccharide Conjugate Vaccine for Broad Serotype Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polysaccharide-based vaccines for group B streptococcus (GBS) do not effectively cover emerging serotypes and are not stable for broad population use, leading to high infection rates in infants and the elderly, and there is a need for stable and easily resuspendable immunogenic compositions.
Innovation Solution
Development of immunogenic compositions comprising GBS polysaccharide-protein conjugates, optionally with an aluminum-based adjuvant, including serotypes Ia, Ib, II, III, IV, V, VI, VII, and VIII, and formulations that ensure stability and easy resuspension.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polysaccharide-based vaccines are used for GBS prevention, then they can provide immune protection, but they do not effectively cover emerging serotypes and lack stability for broad population use
Solution Approach 1:
The vaccine composition is designed to cover multiple GBS serotypes (Ia, Ib, II, III, IV, V, VI, VII, and VIII) simultaneously through a polysaccharide-protein conjugate formulation. This multi-serotype coverage approach enables a single vaccine to provide universal protection against diverse GBS strains, resolving the contradiction between maintaining reliable immune protection and achieving broad serotype adaptability.
2Reliability
If polysaccharide-based vaccines are used, then immune protection is provided, but the formulations are not stable and difficult to resuspend
Solution Approach 1:
The invention employs a composite vaccine formulation that combines polysaccharide-protein conjugates with specific excipients and stabilizers. This composite material approach enhances both the stability of the vaccine during storage and its ease of resuspension upon reconstitution, while maintaining the immune protective function. The composite formulation resolves the contradiction between providing reliable immune protection and ensuring operational ease.
3Reliability
If current polysaccharide-based vaccines are used, then some immune response is generated, but they do not cover emerging serotypes effectively
Solution Approach 1:
The vaccine composition utilizes polysaccharide-protein conjugates with specific molecular characteristics and conjugation ratios that enhance immunogenicity across multiple serotypes. By optimizing parameters such as conjugate structure, protein carrier selection, and polysaccharide chain length, the vaccine achieves both reliable immune response generation and broad serotype coverage including emerging strains.
Data Source
AI summary
The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.